Abstract: An apparatus of tilting a seat cushion of a vehicle, includes a tilting motor, a pinion gear, a sector gear, and a tilting link which perform the tilting operation of the seat cushion and exert a binding force in a tilted state of the seat cushion and are provided to be connected to both of one side and the other side of a seat cushion frame, and has two sector gears positioned on left and right sides and connected to each other by a connection bar so that, by strengthening a binding force of the front portion of the seat cushion, it is possible to secure the safety of passengers in the event of a collision.

Abstract: The present invention relates to a pharmaceutical composition comprising a STT compound as an active ingredient for the prevention or treatment of Parkinson's disease. STT showed neuroprotective effect and apoptosis recovery effect in the Parkinson's disease cell model, restored the reduced motility in the MPTP animal model, and was shown to significantly protect dopamine cells, so it can be used for the prevention and treatment of Parkinson's disease.

Abstract: A method and apparatus for determining a respiration state on the basis of a plurality of biological indicators calculated using bio-signals. The method for determining a respiration state on the basis of a plurality of biological indicators calculated using bio-signals includes collecting a photoplethysmography (PPG) signal measured by a PPG sensor and a cutaneous electric signal measured by an electrodermal activity (EDA) sensor; analyzing the collected PPG signal and cutaneous electric signal and calculating a plurality of biological indicators including a respiration rate; and comprehensively evaluating the plurality of biological indicators to determine a user's respiration state.

Abstract: The present invention relates to a pharmaceutical composition comprising a STT compound as an active ingredient for the prevention or treatment of Parkinson's disease. STT showed neuroprotective effect and apoptosis recovery effect in the Parkinson's disease cell model, restored the reduced motility in the MPTP animal model, and was shown to significantly protect dopamine cells, so it can be used for the prevention and treatment of Parkinson's disease.

Abstract: Disclosed are an apparatus and method for detecting dementia and providing a dementia patient management service.

Abstract: A method and apparatus for determining a respiration state on the basis of a plurality of biological indicators calculated using bio-signals. The method for determining a respiration state on the basis of a plurality of biological indicators calculated using bio-signals includes collecting a photoplethysmography (PPG) signal measured by a PPG sensor and a cutaneous electric signal measured by an electrodermal activity (EDA) sensor; analyzing the collected PPG signal and cutaneous electric signal and calculating a plurality of biological indicators including a respiration rate; and comprehensively evaluating the plurality of biological indicators to determine a user's respiration state.

Abstract: The present invention relates to a composition for detecting a marker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker. More particularly, the present invention relates to a composition for detecting a maker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker, wherein the present invention allows presence and absence of resistance to an HER2 inhibitor, which is typically prescribed to an HER2-positive cancer patient, in an HER2-positive cancer patient to be determined in an easier manner with remarkably high reliability.

Abstract: Provided is a hepatocyte nuclear factor 4 alpha (HNF4-?) antagonist and a use thereof. The HNF4-? antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of HNF4-?, thereby inhibiting the activity of HNF4-?. The HNF4-? antagonist of the present invention can significantly reduce the expression of Wnt5a in a specific manner compared to that of the conventional known HNF4-? antagonists, and can also inhibit the growth of gastric cancer cells. Therefore, the HNF4-? antagonist of the present invention can not only be used as a pharmaceutical composition or a health functional food for preventing and treating cancer but can also be applied to a composition for treating or preventing diseases occurring due to the overexpression of HNF4-?.

Abstract: Provided is a hepatocyte nuclear factor 4 alpha (HNF4-?) antagonist and a use thereof. The HNF4-? antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of HNF4-?, thereby inhibiting the activity of HNF4-?. The HNF4-? antagonist of the present invention can significantly reduce the expression of Wnt5a in a specific manner compared to that of the conventional known HNF4-? antagonists, and can also inhibit the growth of gastric cancer cells. Therefore, the HNF4-? antagonist of the present invention can not only be used as a pharmaceutical composition or a health functional food for preventing and treating cancer but can also be applied to a composition for treating or preventing diseases occurring due to the overexpression of HNF4-?.

Abstract: Disclosed are an apparatus and method for detecting dementia and providing a dementia patient management service.

Abstract: Provided is a hepatocyte nuclear factor 4 alpha (HNF4-?) antagonist and a use thereof. The HNF4-? antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of HNF4-?, thereby inhibiting the activity of HNF4-?. The HNF4-? antagonist of the present invention can significantly reduce the expression of Wnt5a in a specific manner compared to that of the conventional known HNF4-? antagonists, and can also inhibit the growth of gastric cancer cells. Therefore, the HNF4-? antagonist of the present invention can not only be used as a pharmaceutical composition or a health functional food for preventing and treating cancer but can also be applied to a composition for treating or preventing diseases occurring due to the overexpression of HNF4-?.

Abstract: The present invention relates to a composition for detecting a marker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker. More particularly, the present invention relates to a composition for detecting a maker for diagnosing an HER2 inhibitor-resistant cancer, a diagnostic kit including same, and a method for detecting the marker, wherein the present invention allows presence and absence of resistance to an HER2 inhibitor, which is typically prescribed to an HER2-positive cancer patient, in an HER2-positive cancer patient to be determined in an easier manner with remarkably high reliability.